{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T09:55:30Z","timestamp":1781517330019,"version":"3.54.1"},"reference-count":21,"publisher":"MDPI AG","issue":"12","license":[{"start":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T00:00:00Z","timestamp":1781481600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Background: Systematic infectious screening is recommended before initiation of biologic therapies in chronic inflammatory rheumatic diseases (CIRDs), yet the clinical impact of this strategy in low-prevalence settings remains insufficiently characterized. This study aimed to evaluate the proportion of abnormal findings and their impact on treatment management. Methods: We conducted a retrospective single-center study including adult patients with CIRDs who underwent systematic pre-biologic infectious screening between January 2019 and June 2025. Screening included HIV, hepatitis B virus (HBV), hepatitis C virus (HCV), interferon-\u03b3 release assay (IGRA), and chest radiography. The primary outcome was the proportion of abnormal results and their impact on biologic initiation. Results: A total of 418 patients was included (mean age 48.2 \u00b1 14.6 years; 69.1% female). No active HIV, HBV, or HCV infections were detected. Past HBV infection markers were identified in 2.6% of patients, and anti-HCV antibodies in 0.7%, all without detectable viremia. None of these findings required modification of biologic therapy. IGRA positivity was observed in 4.3% of patients and indeterminate results were seen in 3.1%. Preventive antituberculous therapy was initiated in most newly identified IGRA-positive cases, leading to delayed biologic initiation in several patients. Chest radiography yielded limited additional diagnostic value. Conclusions: In this population, systematic pre-biologic infectious screening identified few clinically actionable viral infections, whereas latent tuberculosis screening represented the main determinant of therapeutic modification. These findings support continued emphasis on tuberculosis risk assessment and warrant further prospective studies to evaluate optimized and potentially targeted screening strategies incorporating cost-effectiveness analyses.<\/jats:p>","DOI":"10.3390\/jcm15124631","type":"journal-article","created":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T08:57:58Z","timestamp":1781513878000},"page":"4631","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Relevance of Systematic Pre-Biologic Infectious Screening in Chronic Inflammatory Rheumatic Diseases: A Retrospective Single-Center Study"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5077-1370","authenticated-orcid":false,"given":"Marie","family":"Doussiere","sequence":"first","affiliation":[{"name":"Department of Rheumatology, University Hospital of Amiens, 80000 Amiens, France"},{"name":"GRAP, INSERM U1247, Universit\u00e9 de Picardie Jules Verne, 80000 Amiens, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cl\u00e9mence","family":"Jouret","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, University Hospital of Amiens, 80000 Amiens, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lara","family":"Awad","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, University Hospital of Amiens, 80000 Amiens, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre-Antoine","family":"Bruy","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, University Hospital of Amiens, 80000 Amiens, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laetitia","family":"Diep","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, University Hospital of Amiens, 80000 Amiens, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Jesson","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, University Hospital of Amiens, 80000 Amiens, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Marc","family":"Sobhy-Danial","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, University Hospital of Amiens, 80000 Amiens, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franck","family":"Grados","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, University Hospital of Amiens, 80000 Amiens, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrice","family":"Fardellone","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, University Hospital of Amiens, 80000 Amiens, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3807-545X","authenticated-orcid":false,"given":"Vincent","family":"Go\u00ebb","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, University Hospital of Amiens, 80000 Amiens, France"},{"name":"GRAP, INSERM U1247, Universit\u00e9 de Picardie Jules Verne, 80000 Amiens, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,6,15]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1759720X19868901","DOI":"10.1177\/1759720X19868901","article-title":"When rheumatology and infectious disease come together","volume":"11","author":"Fragoulis","year":"2019","journal-title":"Ther. Adv. Musculoskelet. Dis."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1186\/s13075-019-1997-5","article-title":"Comparing the burdens of opportunistic infections among patients with systemic rheumatic diseases: A nationally representative cohort study","volume":"21","author":"Hsu","year":"2019","journal-title":"Arthritis Res. Ther."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/j.jbspin.2013.09.001","article-title":"Recommendations for using TNF\u03b1 antagonists and French Clinical Practice Guidelines endorsed by the French National Authority for Health","volume":"80","author":"Ardizzone","year":"2013","journal-title":"Jt. Bone Spine"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1136\/ard-2022-223335","article-title":"2022 EULAR recommendations for screening and prophylaxis of chronic and opportunistic infections in adults with autoimmune inflammatory rheumatic diseases","volume":"82","author":"Fragoulis","year":"2023","journal-title":"Ann. Rheum. Dis."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1002\/acr.20576","article-title":"Is routine viral screening useful in patients with recent-onset polyarthritis of a duration of at least 6 weeks? Results from a nationwide longitudinal prospective cohort study","volume":"63","author":"Varache","year":"2011","journal-title":"Arthritis Care Res."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"546","DOI":"10.55563\/clinexprheumatol\/c25fja","article-title":"Prevalence of hepatitis B virus infection and risk of reactivation in rheumatic population undergoing biological therapy","volume":"39","author":"Ditto","year":"2021","journal-title":"Clin. Exp. Rheumatol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1002\/hep.29800","article-title":"Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance","volume":"67","author":"Terrault","year":"2018","journal-title":"Hepatology"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1002\/cld.883","article-title":"Reactivation of Hepatitis B Virus: A Review of Clinical Guidelines","volume":"15","author":"Myint","year":"2020","journal-title":"Clin. Liver Dis."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"39","DOI":"10.2174\/1874312901610010039","article-title":"Hepatitis B Serology in Patients with Rheumatic Diseases","volume":"10","author":"Feuchtenberger","year":"2016","journal-title":"Open Rheumatol. J."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Bellofatto, I.A., Paci, V., Conti, F., Santoboni, G., Sebastiani, G.D., Cattaruzza, M.S., Mazzanti, C., Salemi, S., Sesti, G., and Tesoriere, E. (2025). Coverage and Drivers of Vaccinations in Patients with Autoimmune Rheumatic Diseases: An Italian Multicentric Study. Vaccines, 13.","DOI":"10.3390\/vaccines13121229"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1007\/s10067-025-07350-x","article-title":"Detection of substantial numbers of latent tuberculosis and positive hepatitis B serology results in rheumatology patients preparing to receive intensified immunosuppressive therapy in a low-prevalence country: Why screening still matters","volume":"44","author":"Feuchtenberger","year":"2025","journal-title":"Clin. Rheumatol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.12669\/pjms.41.6.11427","article-title":"Clinical Audit of screening Latent TB, Hepatitis-C, and Occult Hepatitis-B in Rheumatoid arthritis\u2019 patients starting biologic or targeted synthetic DMARDS","volume":"41","author":"Qamar","year":"2025","journal-title":"Pak. J. Med. Sci."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1093\/rheumatology\/ker190","article-title":"Safety of anti-tumour necrosis factor agents in patients with chronic hepatitis C infection: A systematic review","volume":"50","author":"Brunasso","year":"2011","journal-title":"Rheumatology"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.jaad.2017.01.037","article-title":"Risk for hepatitis B and C virus reactivation in patients with psoriasis on biologic therapies: A retrospective cohort study and systematic review of the literature","volume":"77","author":"Snast","year":"2017","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1136\/annrheumdis-2011-200941","article-title":"Screening for latent tuberculosis infection: Performance of tuberculin skin test and interferon-\u03b3 release assays under real-life conditions","volume":"71","author":"Kleinert","year":"2012","journal-title":"Ann. Rheum. Dis."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.1002\/art.34382","article-title":"Interferon-\u03b3 release assay versus tuberculin skin test prior to treatment with golimumab, a human anti-tumor necrosis factor antibody, in patients with rheumatoid arthritis, psoriatic arthritis, or ankylosing spondylitis","volume":"64","author":"Hsia","year":"2012","journal-title":"Arthritis Rheum."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1093\/ecco-jcc\/jjx108","article-title":"The Prevalence of Latent Tuberculosis and Hepatitis B After Systematic Screening of Patients Prescribed Biological Therapy in a Low-endemic Area","volume":"12","author":"Roosen","year":"2018","journal-title":"J. Crohns Colitis"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1093\/ecco-jcc\/jjw129","article-title":"Negative Screening Does Not Rule Out the Risk of Tuberculosis in Patients with Inflammatory Bowel Disease Undergoing Anti-TNF Treatment: A Descriptive Study on the GETAID Cohort","volume":"10","author":"Abitbol","year":"2016","journal-title":"J. Crohns Colitis"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1080\/00365521.2024.2368248","article-title":"The role of chest X-rays when screening for latent tuberculosis infection in patients with inflammatory bowel disease before starting biologic treatment","volume":"59","author":"Ainsworth","year":"2024","journal-title":"Scand. J. Gastroenterol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1093\/ced\/llaf378","article-title":"Are chest X-rays still necessary for prebiologic tuberculosis screening? A retrospective audit","volume":"51","author":"Tan","year":"2025","journal-title":"Clin. Exp. Dermatol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1007\/s00508-022-02062-7","article-title":"National consensus statement by the Austrian Societies for Rheumatology, Pulmonology, Infectiology, Dermatology and Gastroenterology regarding the management of latent tuberculosis and the associated utilization of biologic and targeted synthetic disease modifying antirheumatic drugs (DMARDs)","volume":"134","author":"Rath","year":"2022","journal-title":"Wien. Klin. Wochenschr."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/12\/4631\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T09:44:53Z","timestamp":1781516693000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/12\/4631"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,15]]},"references-count":21,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2026,6]]}},"alternative-id":["jcm15124631"],"URL":"https:\/\/doi.org\/10.3390\/jcm15124631","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,15]]}}}